Previous 10 |
Nano cap Aevi Genomic Medicine (NASDAQ: GNMX ) is up 23% after hours on the heels of its exclusive in-license agreement with Astellas Pharma ( OTCPK:ALPMF ) unit OSI Pharmaceuticals securing global development and commercialization rights to ASP7486 (formerly OSI-027). More n...
PHILADELPHIA , July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of Astellas Pharma Inc. ("Astellas") for the worldwide deve...
CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. As we've seen in recent years, companies are te...
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Park Hotels & Resorts Inc. (NYSE:PK), Planet Fitness, Inc. (NYSE:PLNT), Ae...
Aevi Genomic (NASDAQ: GNMX ): Q3 GAAP EPS of -$0.12. More news on: Aevi Genomic Medicine, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September 30 , 2018 and provided an overview of the Company's recent corporate progress. Thir...
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), Neos Therapeutics, Inc. (NASDAQ:NEOS)...
Thinly traded nano cap Aevi Genomic Medicine ( GNMX +1.9% ) is up on below-average volume following its announcement that Part B of its Phase 2 ASCEND study evaluating AEVI-001 in pediatric and adolescent patients with attention deficit hyperactivity disorder (ADHD) is now fully enrolled...
PHILADELPHIA , Oct. 15, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial. The ASCEND trial is a genomically-guided study in pediatric and adolescent...
News, Short Squeeze, Breakout and More Instantly...
Aevi Genomic Medicine Inc. Company Name:
GNMX Stock Symbol:
NASDAQ Market:
Aevi Genomic Medicine Inc. Website:
-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceu...
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company&...
-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explored for Neurological Assets and Millipred ...